|
Phase 1b/2 study of abemaciclib combined with chemoimmunotherapy in pediatric and young adult patients with relapsed/refractory neuroblastoma (JPCS Part C). |
|
|
No Relationships to Disclose |
|
|
Honoraria - Y-mAbs Therapeutics |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Moderna Therapeutics; Reata Pharmaceuticals |
Consulting or Advisory Role - Bayer; Tempus |
|
Research Funding - Mirati Therapeutics |
|
|
No Relationships to Disclose |
|
Giselle Linda Saulnier Sholler |
Consulting or Advisory Role - Illumina; YmAbs Therapeutics Inc |
Research Funding - YmAbs Therapeutics Inc |
Travel, Accommodations, Expenses - Illumina |
|
|
Employment - Abbvie; Lilly O. |
Stock and Other Ownership Interests - Abbvie; Lilly O. |
|
|
|
Stock and Other Ownership Interests - Lilly O. |
|
|
|
Stock and Other Ownership Interests - Lilly O. |
|
|
No Relationships to Disclose |